Physician profile
Robert R Johnson
NPI 1982780722
$2,604.11
in general payments reported to CMS, 2019-2025
34 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985 · 2020: $196 · 2021: $372 · 2022: $277 · 2023: $331 · 2024: $258 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $578.64 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $367.16 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $188.56 | 2019-2025 | Breztri |
| Abbott Laboratories | $157.86 | 2019-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.77 | 2022 | |
| Abbvie INC. | $127.90 | 2020-2023 | |
| Arbor Pharmaceuticals, INC. | $84.99 | 2019-2021 | |
| Glaxosmithkline, LLC. | $80.04 | 2019-2023 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $76.59 | 2019-2021 | |
| Lilly USA, LLC | $69.89 | 2019-2023 | Mounjaro |
| Organogenesis INC. | $69.29 | 2024 | |
| Sanofi-Aventis U.S. LLC | $65.84 | 2019-2020 | |
| Pfizer INC. | $55.24 | 2019-2024 | |
| Eisai INC. | $51.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.96 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46.76 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.24 | 2019 | |
| Sanofi Pasteur INC. | $40.54 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $38.32 | 2021 | |
| Azurity Pharmaceuticals, INC. | $38.03 | 2025 | Alvesco |
| Currax Pharmaceuticals LLC | $29.81 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $26.92 | 2019 | |
| Allergan, INC. | $26.00 | 2019-2020 | |
| Mylan Specialty L.P. | $19.28 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.58 | 2025 | Gvoke Hypopen |
| Ironshore Pharmaceuticals INC. | $16.32 | 2019 | |
| Bausch Health US, LLC | $15.88 | 2019 | |
| Intra-Sana Laboratories | $13.80 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Almatica Pharma LLC | $13.79 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.27 | 2023 | Nuzyra |
| Genentech USA, INC. | $12.90 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.84 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.31 | 2020 | |
| Zyla Life Sciences, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.